Document Type : Research articles


1 HSU Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Radiation Oncology, Ankara, Turkey.

2 HSU Kartal Dr. Lutfi Kirdar Training and Research Hospital, Radiation Oncology, Istanbul, Turkey.


Introduction and Objectives: The latest technology and current treatments are used in the treatment of cancer in Turkey; however, oncological hyperthermia devices are currently not available. This study aimed to demonstrate the necessity of oncological hyperthermia devices in Turkey where cancer treatment is performed effectively. In this direction, some important oncological hyperthermia centers have been examined to what kind of planning can be developed in this country.
Materials and Methods: The data were collected regarding the number of patients who had undergone hyperthermia during the treatment of cancer and the distribution of oncological diagnoses, devices per population, and rate of hyperthermia use. Subsequently, a model was prepared for Turkey, and an evaluation was performed on the number of cancer patients that can be applied to this treatment and the need for the number of oncological hyperthermia devices.
Results: According to the data obtained, an average of 375 patients are treated annually per hyperthermia device in relevant centers. When a similar projection is applied for Turkey, hyperthermia treatment can be applied to an average of 400 patients annually with 0.18 hyperthermia devices per one million population. According to this result, considering the population and the annual cancer diagnosis rates, it is predicted that 13 deep regional hyperthermia devices are required across the country.
Conclusion: The presence of deep regional hyperthermia devices in comprehensive oncology centers plays an effective role in oncological treatment with modern radiotherapy devices. This condition along with the sufficient number of radiation oncologists will significantly benefit the capacity to provide oncological treatment options holistically.


  1. Bruggmoser G, Bauchowitz S, Canters R, Crezee H, Ehmann M, Gellermann J, et al. Guideline for the clinical application, documentation and analysis of clinical studies for regional deep hyperthermia. Strhlenther Oncol. 2012;188 Suppl 2:198-211. doi: 10.1007/s00066-012-0176-2. [PubMed: 22926657].
  2. Datta NR, Bodis S. Hyperthermia with radiotherapy reduces tumour alpha/beta: Insights from trials of thermoradiotherapy vs radiotherapy alone. Radiother Oncol. 2019;138:1-8. doi: 10.1016/j.radonc.2019.05.002. [PubMed: 31132683].
  3. Hermisson M, Weller M. Hyperthermia enhanced chemosensitivity of human malignant glioma cells. Anticancer Res. 2000;20(3A):1819-23. [PubMed: 10928113].
  4. Kroesen M, Mulder HT, van Holthe JM, Aangeenbrug AA, Mens JW, van Doorn HC, et al. The Effect of the Time Interval Between Radiation and Hyperthermia on Clinical Outcome in 400 Locally Advanced Cervical Carcinoma Patients. Front Oncol. 2019;9:134. doi: 10.3389/fonc.2019.00134. [PubMed: 30906734].
  5. Istomin YP, Zhavrid EA, Alexandrova EN, Sergeyeva OP, Petrovich SV. Dose enhancement effect of anticancer drugs associated with increased temperature in vitro. Exp Oncol. 2008;30(1):56-9. [PubMed: 18438342].
  6. Issels RD. Hyperthermia adds to chemotherapy. Eur J Cancer. 2008;44(17):2546-54. doi: 10.1016/j.ejca.2008.07.038. [PubMed: 18789678].
  7. Gerweck LE. Hyperthermia in cancer therapy: The biological basis and unresolved questions. Cancer Res. 1985;45(8):3408-14. [PubMed: 3893686].
  8. Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002;3(8):487-97. doi: 10.1016/s1470-2045(02)00818-5. [PubMed: 12147435].
  9. Crezee H, van Leeuwen CM, Oei AL, Stalpers LJ, Bel A, Franken NA, et al. Thermoradiotherapy planning: integration in routine clinical practice. Int J Hyperthermia. 2016;32(1):41-9. doi: 10.3109/02656736.2015.1110757. [PubMed: 26670625].
  10. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. doi: 10.3322/caac.21262. [PubMed: 25651787].
  11. Turkey Cancer Statistics, RT Ministry of Health Turkish Public Health Institution, Ankara, 2017[WU1] 
  12. Ott OJ, Schmidt M, Semrau S, Strnad V, Matzel KE, Schneider I, et al. Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus. Strahlenther Onkol. 2019;195(7):607-14. doi: 10.1007/s00066-018-1396-x. [PubMed: 30390114].
  13.  De-Colle C, Weidner N, Heinrich V, Brucker S, Hahn M, MacMillan K, et al. Hyperthermic chest wall re irradiation in recurrent breast cancer: a prospective observational study. Strahlenther Onkol. 2019;195(4):318-26. doi: 10.1007/s00066-018-1414-z. [PubMed: 30607453].
  14.  Merten R, Ott O, Haderlein M, Bertz S, Hartmann A, Wullich B, et al. Long-term experience of chemoradiotherapy combined with deep regional hyperthermia for organ preservation in high-risk bladder cancer (Ta, Tis, T1, T2). Oncologist. 2019;24(12):e1341-50. doi: 10.1634/theoncologist.2018-0280. [PubMed: 31292267].
  15.  He M, Sun J, Zhao D, He H, Wang B, Xu L, et al. Modified-FOLFIRINOX combined with deep regional hyperthermia in pancreatic cancer: a retrospective study in Chinese patients. Int J Hyperthermia. 2019;36(1):394-402. doi: 10.1080/02656736.2019.1579371. [PubMed: 30917701].
  16. Engelhardt R. Hyperthermia and drugs. Recent Results Cancer Res. 1987;104:136-203. doi: 10.1007/978-3-642-82955-0_5. [PubMed: 3296049].
  17. Dahl O. Interaction of hyperthermia and chemotherapy. Recent Results Cancer Res. 1988;107:157-69. doi: 10.1007/978-3-642-83260-4_23. [PubMed: 3287520].
  18. Hahn GM. Potential for therapy of drugs and hyperthermia. Cancer Res. 1979;39(6 Pt):2264-8. [PubMed: 87263].
  19. Urano M, Kuroda M, Nishimura Y. For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia. 1999;15(2):79-107. doi: 10.1080/026567399285765. [PubMed: 10323618].
  20. Issels RD. Hyperthermia and thermochemotherapy. Cancer Treat Res. 1993;67:143-60. doi: 10.1007/978-1-4615-3082-4_10. [PubMed: 8102871].
  21. ssels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high risk soft-tissue sarcoma; a randomised phase 3 multicenter study. Lancet Oncol. 2010;11(6):561-70. doi: 10.1016/S1470-2045(10)70071-1. [PubMed: 20434400].
  22. Wendtner CM, Abdel-Rahman S, Krych M, Baumert J, Lindner LH, Baur A, et al. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol. 2002;20(14):3156-64. doi: 10.1200/JCO.2002.07.146. [PubMed: 12118030].
  23. Sauer R, Creeze H, Hulshof M, Issels R, Ott O. Concerning the final report "Hyperthermia: a systematic review" of the Ludwig Boltzmann Institute for Health Technology Assessment, Vienna, March 2010. Strahlenther Onkol. 2012;188(3):209-13. doi: 10.1007/s00066-012-0072-9. [PubMed: 22318331].
  24.  Kok HP, Crezee J. A comparison of the heating characteristics of capacitive and radiative superficial hyperthermia. Int J Hyperthermia. 2017;33(4):378-86. doi: 10.1080/02656736.2016.1268726. [PubMed: 27951733].
  25.  Kok HP, Navarro F, Strigari L, Cavagnaro M, Crezee J. Locoregional hyperthermia of deep-seated tumours applied with capacitive and radiative systems: a simulation study. Int J Hyperthermia. 2018;34(6):714-30. doi: 10.1080/02656736.2018.1448119. [PubMed: 29509043].
  26. Kurpeshev OK, Van der Zee J, Cavagnaro M. Hyperthermia for Deep Seated Tumours-Possibilities of Heating with Capacitive Devices. Медицинская радиология и радиационная безопасность. 2019;64(4):64–75.